Diabetes is associated with increased risk of hepatocellular carcinoma in non-alcoholic steatohepatitis with cirrhosis—implications for surveillance and future pharmacotherapy

Hepatocellular carcinoma (HCC) is the most common liver-related complication seen in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) (1). NASH is strongly associated with type 2 diabetes mellitus (T2DM) but it has also been apparent for a number of years that T2DM is associated with an increased risk of HCC independent of the presence of NASH (2).